Paper Details

  1. Home
  2. Paper Details

Enhancing neural transmission in multiple sclerosis (4-aminopyridine therapy).

Author: GoodmanAndrew D, StoneRobert Thompson

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Dalfampridine is a new medication that helps improve walking speed in people with multiple sclerosis (MS) by improving communication between nerves. Clinical trials have shown that dalfampridine improves walking speed by 25% in about a third of MS patients, regardless of their disease stage. It also improves how patients feel about their ability to walk and may strengthen their legs. The most serious side effect is an increased risk of seizures, which happens more often at high doses. Other common side effects include falls, urinary tract infections, dizziness, insomnia, and headaches.
Paper Details　
Original Abstract of the Article :
Enhancing neural transmission by improving axonal conduction and synaptic neurotransmitter release is a novel strategy to improve symptoms in multiple sclerosis. Dalfampridine (4-aminopyridine extended-release) is a first-in-class medication that targets the damaged nervous system through blockage o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557354/

データ提供：米国国立医学図書館（NLM）

Enhancing Neural Transmission in Multiple Sclerosis

This article delves into the intriguing world of multiple sclerosis (MS) treatment, exploring the potential of enhancing neural transmission as a novel therapeutic strategy. The researchers focus on dalfampridine (4-aminopyridine extended-release), a medication that targets the damaged nervous system in MS by blocking potassium channels, thereby improving axonal conduction and synaptic neurotransmitter release.

Dalfampridine: A New Path for Multiple Sclerosis Treatment

This study, like a camel finding a new route through the desert, explores a novel approach to managing multiple sclerosis. The researchers have demonstrated that dalfampridine, by improving axonal conduction and synaptic neurotransmitter release, can enhance walking speed and improve the quality of life for individuals with MS.

Improving Walking Speed: A Milestone in MS Treatment

The study highlights the significant benefits of dalfampridine in improving walking speed and reducing the impact of MS on mobility. This research underscores the potential of targeting neural transmission as a strategy for managing the debilitating symptoms of this neurological condition.

Dr. Camel's Conclusion

This study, like a camel finding a refreshing oasis after a long journey, offers hope for individuals struggling with multiple sclerosis. The research showcases the potential of dalfampridine to enhance neural transmission, improving mobility and quality of life for those with this debilitating condition.

Date :
  1. Date Completed 2013-07-29
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23184313

DOI: Digital Object Identifier

PMC3557354

Related Literature

Article Analysis
・Side Effects of dalfampridine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.